Fig. 3From: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trialSurvival outcomes in patients with RM-NPC treated with anlotinib. A Progression-free survival (PFS). B Overall survival (OS). Number of patients at risk at indicated time points are shown beneath the x-axisBack to article page